Special Report: Countries, companies risk billions in race for coronavirus vaccine
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following Court Decision
April 28, 2020 6:53 AM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $168.00 price target on Johnson & Johnson (NYSE: JNJ) following the courts much-anticipated Daubert decision, which Chen thinks turned out favorably for the company. The judge decided that certain plaintiff expert witnesses did not present... More
Mizuho Securities Reiterates Buy Rating on Pfizer (PFE) Ahead of 1Q Report
April 27, 2020 6:44 AM EDTMizuho Securities analyst Vamil Divan reiterated a Buy rating and $42.00 price target on Pfizer (NYSE: PFE) ahead of the company's 1Q earnings report. The stock has had a nice recovery over the past month but remains down ~4.5% YTD. The company's is scheduled to report... More
